SEC Form 4 · accession 0001213900-18-009536
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1,F2,F3,F4,F5 | Jul 19, 2018 | S | 100,000 | $18.8994 | D | 8,399,920 | D | |
| COMMON STOCKF1,F2,F3,F4,F5 | Jul 20, 2018 | S | 26,742 | $19.2134 | D | 8,373,178 | D |
Table II — derivative securities
Explanation of responses
- F1The prices reported in Column 4 are weighted average prices. The shares were sold on 07/19/2018 at prices ranging from $18.6 to $19.305, inclusive, and on 07/20/2018 at prices ranging from $19.2 to $19.28, inclusive.
- F2The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above.
- F3Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.
- F4Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed.
- F5Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Remarks
Exhibit Index Exhibit 24.1 - Power of Attorney, dated February 2, 2018, made by Marcin Czernik and Chione Limited in favor of Simon Prisk (previously filed) Exhibit 24.2 - Power of Attorney, dated February 2, 2018, made by Andreas Hadjimichael and Chione Limited in favor of Simon Prisk (previously filed) Exhibit 24.3 - Power of Attorney, dated February 2, 2018, made by George Hadjimichael and Chione Limited in favor of Simon Prisk (previously filed) Exhibit 24.4 - Power of Attorney, dated February 2, 2018, made by Wiaczeslaw Smolokowski in favor of Simon Prisk Exhibit (previously filed) 99.1 - Joint Filer Information (filed herewith) Exhibit 99.2 - Joint Filing Agreement (previously filed ). All previously filed exhibits were filed with the Schedule 13G/A of the reporting persons, filed on February 14, 2018, except that the Joint Filing Agreement was filed with the Form 4 of the reporting persons, filed on July 18, 2018.